Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | BCHE | P06276 | 1/20 | 0.80 |
| ▸ | ACHE | P22303 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | DRD4 | P21917 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373104 | 0.95 | DRD2 (0.89) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL19902111 | 0.95 | KCNH2 (0.83) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL21125881 | 0.95 | KCNH2 (0.83) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL29376236 | 0.94 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL12807694 | 0.92 | KDM4E (0.86) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL29411700 | 0.91 | KCNH2 (0.96) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL18179207 | 0.91 | DRD2 (0.89) | DRD2DRD1BCHEACHEKCNH2 | |
| SCHEMBL29052976 | 0.91 | DRD2 (0.89) | DRD2DRD1BCHEACHEKCNH2 | |
| Laudanidine SCHEMBL18187574 | 0.90 | DRD2 (0.95) | DRD2DRD1BCHEACHEKCNH2 | |
| Laudanidine SCHEMBL15696580 | 0.89 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250137021-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2025-05-01 | — | — | US | disclosed |
| US-12180525-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| WO-2024073755-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4253525-A2 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022109194-A9 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-3294865-B1 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | UNIV LELAND STANFORD JUNIOR (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230104286-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11396668-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220162656-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | DRD2 618/4885DRD1 532/4885BCHE 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.